Quick Answer
VYNE Therapeutics Inc. reported Stockholders Equity of $27.77 million for the year ending 2025.
- VYNE Therapeutics Inc. showed a decrease of -46.7% in Stockholders Equity from 2024 to 2025.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $165.70 million | Q2 2018: $158.19 million | Q3 2018: $146.88 million | Q1 2019: $78.00 million | Q2 2019: $60.38 million | Q3 2019: $53.53 million | Q1 2020: $69.54 million | Q2 2020: $71.53 million | Q3 2020: $49.52 million | Q1 2021: $92.90 million | Q2 2021: $74.89 million | Q3 2021: $58.89 million | Q1 2022: $55.73 million | Q2 2022: $48.36 million | Q3 2022: $40.07 million | Q1 2023: $26.43 million | Q2 2023: $17.27 million | Q3 2023: $11.51 million | Q1 2024: $83.37 million | Q2 2024: $74.87 million | Q3 2024: $63.54 million | Q1 2025: $44.13 million | Q2 2025: $38.88 million.
- Over the full 12 years of available data (2014 to 2025), VYNE Therapeutics Inc.'s Stockholders Equity has grown by 343.3%.
- Historical annual values: Fiscal year 2025: $27.77 million | Fiscal year 2024: $52.09 million | Fiscal year 2023: $88.74 million | Fiscal year 2022: $31.20 million | Fiscal year 2021: $48.64 million | Fiscal year 2020: $37.49 million | Fiscal year 2019: $17.58 million | Fiscal year 2018: $92.18 million | Fiscal year 2017: $68.60 million | Fiscal year 2016: -$29.44 million | Fiscal year 2015: -$15.95 million | Fiscal year 2014: -$11.41 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: